Verve Therapeutics

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan and Burt A. Adelman in 2018 and is headquartered in Boston, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.

Global X Genomics & Biotechnology ETF

Intellia Therapeutics

Gene editing is revolutionizing medicine. For example, just weeks ago, the U.S. Federal Drug Administration approved a new gene-editing treatment for sickle cell disease and transfusion-dependent beta-thalassemia, a genetic disorder that prevents the production of hemoglobin in the blood and requires regular blood transfusions.

3 Gene Editing Stocks With Unprecedented Surge Potential

Caribou Biosciences

There's a new bull market, and it's lifting biotech stocks once again. Caribou Biosciences already has some good data and regulatory buy-in.

2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare

BOSTON, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 11:30 a.m. ET in New York.

Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example.

3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential

Asensus Surgical

Editas Medicine

Hologic

Illumina

Johnson & Johnson

Moderna

With so many question marks facing the viability of the equities sector, concerned investors may want to turn their attention to compelling healthcare stocks. Primarily, the sector benefits from permanent relevance.

7 Mighty Healthcare Stocks Changing the Game of Medicine

Beam Therapeutics

The promise of gene editing is moving closer to being a reality. If you're an investor with a speculative appetite and appropriate risk tolerance, you may want to consider a long position in gene editing stocks.

3 Stocks to Buy in the Booming Field of Gene Editing

LOS ANGELES, CA / ACCESSWIRE / January 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Verve Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Archer Aviation

Cerus

Ginkgo Bioworks Holdings

Invitae

Cathie Wood's ARK Innovation ETF isn't afraid to go against Wall Street and the S&P 500. But in some cases, the consensus agrees with the famed ETF manager.

Analysts Agree These 8 Cathie Wood Stock Picks Will Soar In 2024

BOSTON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 4:30 p.m. PT in San Francisco.

Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Ionis Pharma

Iovance Biotherapeutics

Intra-Cellular Therapies

Madrigal Pharmaceuticals

SPDR S&P Biotech ETF

The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a challenging year, there have been some winners in the biotech sector - I have been fortunate to share a few successful tips with Seeking Alpha readers.

3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations

Verve Therapeutics (VERV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Verve Therapeutics (VERV) Moves to Buy: Rationale Behind the Upgrade

The average of price targets set by Wall Street analysts indicates a potential upside of 217.7% in Verve Therapeutics (VERV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Verve Therapeutics (VERV) Could Surge 217.73%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 260.3% in Verve Therapeutics (VERV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Verve Therapeutics (VERV) Could Rally 260.31%: Here's is How to Trade

LOS ANGELES, CA / ACCESSWIRE / December 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Verve Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Verve Therapeutics, Inc. released positive interim data from its phase 1b heart-1 study using VERVE-101 for treating HeFH patients; LDL-C reduced by as much as 55% after a single dose. IND clearance for VERVE-101 in the U.S. opens up the inclusion of U.S. trial sites to the phase 1b heart-1 study, along with a possible pathway for FDA approval. The company has additional candidates in its pipeline being used to treat patients with elevated levels of LDL-C, which are VERVE-102 and VERVE-201, respectively.

Verve: Potential To Advance Gene Based Editing Drugs For ASCVD

Verve Therapeutics is a biotechnology company focused on developing single-course gene editing medicines for cardiovascular disease (CVD), particularly atherosclerotic cardiovascular disease (ASCVD). The company has advanced its first cardiovascular disease base editor, VERVE101, into a global Phase 1b clinical trial, demonstrating significant progress in gene editing for CVD. Verve's proprietary lipid nanoparticle delivery technology, GalNAcLNP, is central to their leading drug candidates, including VERVE101 and VERVE102 targeting PCSK9, and VERVE201 targeting ANGPTL3.

Verve Therapeutics: Revolutionizing Cardiovascular Health Via Gene Therapy

ARK Genomic Revolution Multi-Sector ETF

CRISPR Therapeutics

Robinhood

Eli Lilly

Prime Medicine Inc

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Genomic medicine is predicted to become a multi-billion-dollar industry. Even so, this market will probably take years to mature, and risks abound as a result.

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.

BOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the closing of its previously announced underwritten public offering of 14,375,000 shares of its common stock at a public offering price of $10.00 per share, which includes 1,875,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions. The total gross proceeds of the public offering were approximately $143.8 million, before deducting underwriting discounts and commissions and offering expenses payable by Verve. All of the shares in the public offering were sold by Verve.

Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement

LOS ANGELES, CA / ACCESSWIRE / December 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Verve Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Verve Therapeutics is focused on developing in vivo gene editing therapies for cardiovascular disease. The company aims to disrupt the chronic care model for CVD by targeting genes related to atherosclerotic cardiovascular disease. Verve's interim data from its phase 1b clinical trial showed promising efficacy in reducing LDL-C, but safety concerns caused a sell-off in its stock.

Verve Therapeutics: Lilly's Experience A Welcome Addition To In Vivo Gene Therapy Program

BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, for total gross proceeds of $125.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Verve. All of the shares in the public offering are being sold by Verve. In addition, Verve has granted the underwriters a 30-day option to purchase up to 1,875,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement

BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Verve. In addition, Verve expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering at the public offering price, less underwriting discounts and commissions.

Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

Does Verve Therapeutics (VERV) Have the Potential to Rally 260.31% as Wall Street Analysts Expect?

LOS ANGELES, CA / ACCESSWIRE / November 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Verve Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Verve Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

News for Verve Therapeutics Stock (VERV)